Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis

Rituximab (RTX) may benefit patients with glomerular disease who suffer from focal segmental glomerular sclerosis (FSGS) or minimal change disease (MCD). Here, we have described our experience treating 6 FSGS and 9 MCD patients with steroid-dependent/refractory nephrotic syndrome (NS) with RTX. Pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Ren, Hong, Lin, Li, Shen, Pingyan, Li, Xiao, Xie, Jingyuan, Pan, Xiaoxia, Zhang, Wen, Chen, Nan
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper: Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5706808/
https://ncbi.nlm.nih.gov/pubmed/29212162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21833
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados